# A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection

> **NCT04585789** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 24 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** JNJ-73763989
- **DRUG:** JNJ-56136379
- **DRUG:** Entecavir (ETV)
- **DRUG:** Tenofovir disoproxil
- **DRUG:** Tenofovir alafenamide (TAF)
- **DRUG:** PegIFN-alpha-2a (Optional)

## Key facts

- **NCT ID:** NCT04585789
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-11
- **Primary completion:** 2023-02-08
- **Final completion:** 2024-01-09
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04585789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04585789, "A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04585789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*